Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers

Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers

Abstract Background Metaplastic breast cancer (MBC) is a rare form of breast cancer characterized by an aggressive clinical presentation, with a poor response to standard chemotherapy. MBCs are typically triple-negative breast cancers (TNBCs), frequently with alterations to genes of the PI3K-AKT-mTO...

Full description

Bibliographic Details
Main Authors: F. Coussy, R. El Botty, M. Lavigne, C. Gu, L. Fuhrmann, A. Briaux, L. de Koning, A. Dahmani, E. Montaudon, L. Morisset, L. Huguet, L. Sourd, P. Painsec, S. Chateau-Joubert, T. Larcher, S. Vacher, S. Melaabi, A. Vincent Salomon, E. Marangoni, I. Bieche
Format: Article
Language:English
Published: BMC 2020-02-01
Series:Journal of Hematology & Oncology
Subjects:
Metaplastic breast cancer
PI3K inhibitor
MEK inhibitor
Combination of targeted therapies
Online Access:http://link.springer.com/article/10.1186/s13045-020-0846-y

Internet

http://link.springer.com/article/10.1186/s13045-020-0846-y

Similar Items